Evidence map›Paper›PMID 27787577›Full record

ArticleCancer immunology, immunotherapy : CII2017

Alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 can support immune responses toward tumors overexpressing ganglioside D3 in mice.

Jonathan M Eby, Levi Barse, Steven W Henning, Martijn J W E Rabelink, Jared Klarquist, Emily R Gilbert, Adam M Hammer, Manuel F Fernandez, Nathan Yung, Safia Khan and 6 more

Open access · greenAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 2 countries.

Jonathan M EbyOncology Research Institute, Loyola University Medical Center, Loyola University Chicago, Rm 203, 2160 S. 1st Avenue, Maywood, IL, 60153, USA.
Levi BarseOncology Research Institute, Loyola University Medical Center, Loyola University Chicago, Rm 203, 2160 S. 1st Avenue, Maywood, IL, 60153, USA.
Steven W HenningOncology Research Institute, Loyola University Medical Center, Loyola University Chicago, Rm 203, 2160 S. 1st Avenue, Maywood, IL, 60153, USA.
Martijn J W E RabelinkDepartment of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands.
Jared KlarquistOncology Research Institute, Loyola University Medical Center, Loyola University Chicago, Rm 203, 2160 S. 1st Avenue, Maywood, IL, 60153, USA.
Emily R GilbertDepartment of Medicine, Loyola University Chicago, Maywood, IL, USA.
Adam M HammerOncology Research Institute, Loyola University Medical Center, Loyola University Chicago, Rm 203, 2160 S. 1st Avenue, Maywood, IL, 60153, USA.
Manuel F FernandezOncology Research Institute, Loyola University Medical Center, Loyola University Chicago, Rm 203, 2160 S. 1st Avenue, Maywood, IL, 60153, USA.
Nathan YungOncology Research Institute, Loyola University Medical Center, Loyola University Chicago, Rm 203, 2160 S. 1st Avenue, Maywood, IL, 60153, USA.
Safia KhanOakton Community College, Des Plaines, IL, USA.
Hannah G MillerIllinois Mathematics and Science Academy, Aurora, IL, USA.
Edward R KesslerDepartment of Medicine, Loyola University Chicago, Maywood, IL, USA.
Elizabeth Garrett-MayerDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
Daniel F DillingDepartment of Medicine, Loyola University Chicago, Maywood, IL, USA.
Rob C HoebenDepartment of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands.
I Caroline Le PooleOncology Research Institute, Loyola University Medical Center, Loyola University Chicago, Rm 203, 2160 S. 1st Avenue, Maywood, IL, 60153, USA. ilepool@luc.edu.
Loyola University Chicago · USLoyola University Medical Center · USLeiden University Medical Center · NLIllinois Mathematics and Science Academy · USMedical University of South Carolina · USOakton Community College · USUniversity of Colorado Denver · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An immunotherapeutic strategy is discussed supporting anti-tumor activity toward malignancies overexpressing ganglioside D3. GD3 can be targeted by NKT cells when derived moieties are presented in the context of CD1d. NKT cells can support anti-tumor responses by secreting inflammatory cytokines and through cytotoxicity toward CD1d

Indexed as

AnimalsBiolisticsCell Line, TumorGangliosidesHEK293 CellsHumansMelanomaMelanoma, ExperimentalMiceMice, Inbred C57BLMice, KnockoutSialyltransferasesVaccines, DNAalpha-N-acetylneuraminate alpha-2,8-sialyltransferaseganglioside, GD3GangliosidesSialyltransferasesST8SIA5 protein, humanVaccines, DNAAdenovirusGanglioside D3Neuroendocrine tumorsSialyltransferaseVaccine

Identifiers

PMID27787577
PMCPMC11028533
OpenAlexW2543805769

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.